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Dr Brian F. Buxton (Richmond, Victoria, Australia). Thank
you, Mr. Chairman. I would like to commence by thanking Dr
Hwang for sending me the full paper last week.
Fundamentally, this is a very important randomized, controlled
trial and has the potential of being one of the major trials comparing
the saphenous vein with an arterial graft. So far as I am aware, there
has been no other similar trial. The study was performed in the set-
ting of a left internal thoracic Y-graft configuration. The coronary
bypass procedurewas performed off-pump by an experienced group
of coronary artery bypass surgeons in patients with isolated coro-
nary artery disease. The primary end points, as you saw, were graftThe Journal of Thoracic and Carpatency and major clinical events at 1 year. The initial angiographic
assessment was performed in the week after operation. Stenosis
>75% and occlusion were defined as occlusion.
The paper is well written. The relative graft patencies were de-
termined using a noninferiority statistical model with a difference
of8% between the saphenous vein and the right internal thoracic
artery.
Mr. Chairman, before I go any further, I would like to make one
comment. If we are to improve our techniques with randomized,
controlled trials, what we need to do is have both an end point
with functional and anatomic definitions. For example, fractional
flow reserve is a way we can quantify the impact of the collateral
circulation on study grafts, and the results should be incorporated
in the composite end point. Assessing the collateral circulation by
estimating the degree of stenosis alone in the native circulation is
unreliable, particularly in the range between 50% and 90%.
The authors have indicated that the sample size of 106 patients
in each arm factored in the appropriate power calculation and sam-
ple size, and has allowed for patient dropouts. The term ‘‘interim
analysis’’ is better avoided, and I think should be described as the
early analysis. I disagree with the conclusion in the abstract that it
was shown that noninferiority was not established, because this
was not powered for in the early or interim analysis, but only for
the results at 1 year. The authors have correctly withdrawn that
statement from their presentation.
I have 3 questions that I would like to ask separately. First of all,
there are 5 current, randomized, controlled trials looking at the pa-
tency of arterial and saphenous vein grafts. Each of these trials has
a different definition of graft patency, making interpretation and
meta-analysis very difficult. Could the authors clarify the definition?
For example, is a graftwith a stenosis of 80%patent or is it occluded?
Dr Hwang. Thank you for your nice comments. As you indi-
cated, first of all, we omitted the term ‘‘noninferiority’’ in the pre-
sentation slides this afternoon and in the final submitted
manuscript. Our statistician also advised us that the term should
be used after obtaining the primary end point, the 1-year angio-
graphic patency rate and its confidence interval.
Regarding your first question, graft patency was graded in the
manner described by FitzGibbon and his colleagues. Grades A
and B were treated as patent, and grade O, anastomosis, which in-
cluded stenosis of 75% of the vessel diameter or a totally oc-
cluded graft, was treated as occluded. However, we did not find
any graft with stenosis of 75% during the study period.
Dr Buxton. The FitzGibbon classification, A is completely pat-
ent, B is a stenosis>50% and O is an occlusion. So there is a slight
difference, but basically you have a composite end point of occlu-
sion and>75% stenosis, which is acceptable.
The second question I have is, how do the authors arrive at the
noninferiority margin of8% for the saphenous vein versus the
right internal thoracic artery at the 1-year follow-up?
Dr Hwang. You mean the inferiority margin of8%?
Dr Buxton. Yes. The margin is quite high for a trial that you
designated the end point as being 12 months.
Dr Hwang. Inferiority margin is not an exact percentage that
we expect to obtain; it is the lowest margin of confidence interval.
The saphenous vein patency rates in other previous studies, includ-
ing randomized and nonrandomized studies, were those of the sa-
phenous vein, which was used as an aortocoronary bypass afterdiovascular Surgery c Volume 144, Number 5 1033
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those. We harvest the saphenous vein with minimal manipulation,
avoid the intraluminal dilatation, and use it as a Y-composite graft.
We expect a 1-year patency rate of the saphenous vein to be 93%.
We assume that a 93% patency rate with a confidence interval from
87 to 99, which is 6%, is acceptable to demonstrate noninferior-
ity of the saphenous vein, compared with the right internal thoracic
artery with a patency rate of 95%. There were no references to de-
cide inferiority margin.
Dr Buxton. The only point I am making is that some of the
older observational data suggest high failure rates of saphenous
vein grafts whereas the current, randomized, controlled trials
that we have of Hayward, Goldman, and Collins suggest that, in
fact, the current failure rate of saphenous vein grafts in this setting
has improved or is better than historical data. In other words, the
results of saphenous vein grafting in this setting has lower rates
and therefore it is going to make it more difficult for you to achieve
your end point at 12 months.
And the third question is, if this noninferiority has not been
reached or not demonstrated at 1 year, what plans do you have
to extend the trial to perhaps 5 years, if required?
Dr Hwang.We believe that we will get noninferiority results at
1 year. Regardless of the 1-year result of this randomized trial, we
are planning to extend the study duration and we are going to per-
form follow-up angiograms at 5 years after surgery.
Dr Buxton. Thank you very much and I look forward to hearing
the late results.
DrRobert A. Dion (Genk, Belgium). I just want to make a com-
ment about the technique. You insist on the fact that 36% of your
right mammary artery grafts were too short to perform a full revas-
cularization. When I have to go very far on the inferior wall of the
left ventricle with a free right internal mammary artery, I do the Y
anastomosis last, because it allows me to use, optimally and se-
quentially, the right mammary artery and to decide at the end
where I perform the anastomosis on the left mammary artery
and which orientation I choose. During the past 10 years I very
rarely needed to use a third graft, even in dilated ventricles. It is
indeed technically easier to perform the Y anastomosis at first,
but I think you win efficacy in using the length of the right mam-
mary artery if you do it last. Thank you.
Dr Hwang. Thank you, Dr Dion. I remember that you did
have the same comment to my presentation at the Society of
Thoracic Surgeons meeting last year. We always perform the Y
anastomosis before committing distal anastomoses. By perform-
ing the YAnastomosis first, it is possible to perfuse the coronary
arteries after each distal anastomosis during off-pump coronary
revascularization. We frequently observe that hemodynamic in-
stabilities become stable after each anastomosis, especially while
displacing the heart and grafting the lateral or posterior wall ves-
sels. In addition, the average length of the harvested, skeleton-
ized right ITA was approximately 15 cm and it was not always
enough to revascularize the lateral and posterior–inferior coro-
nary arteries completely in the dilated ventricle.
Dr Guo-Wei He (Tianjin, China). This is a very nice study, par-
ticularly because it is a randomized study. My question, actually, is
very similar to Professor Brian Buxton’s third question. You have
to look at the long-term results for re-angiogram. You never an-
swered that. I would like to make a comment on that.1034 The Journal of Thoracic and Cardiovascular SurThe early occlusion of the graft is largely a result of technical
problems, but the long-term patency and the occlusion rate for
the long term largely depends on the biological characteristics of
the graft.
Now, 10, 15 years ago we did a series of studies looking at the
endothelial function of our grafts, including arterial and saphenous
vein grafts, and we have found that the endothelium of the arterial
graft, including the internal mammary artery and the radial artery
and the gastroepiploic artery, all these arterial grafts release more
nitric oxide as well as endothelium-derived hyperpolarizing factor
than the saphenous veins. That will play a major role in the long
term, beyond 5 or 10 years, as far as the occlusion rates or patency
rates are concerned.
So my comment is you really cannot make a conclusion for the
early 1-year angiogram to say the right mammary or left mammary
artery patency rates are the same as the saphenous vein. So my
comment is really we have to look at the long-term patency.
Dr Hwang. Thank you for your comment. I totally agree with
you.
Dr David Glineur (Brussels, Belgium). Last year we pub-
lished in the Journal of Thoracic and Cardiovascular Surgery
a study on fractional flow reserve measurements with this config-
uration. We concluded that this configuration works perfectly, but
we also found that if you graft a not very stenosed left anterior de-
scending coronary artery, you could have a steal phenomenon in
the vein group. Have you seen this phenomenon at the angio con-
trol at 1 day? Do you think it could be a problem for such
a configuration?
Dr Hwang. Thank you for your question. We did not observe
any flow steal phenomenon on early postoperative angiograms. In-
stead, we observed a few patients who showed bidirectional com-
petition (early washout of grafted coronary artery on graft
angiogram and retrograde filling of graft on native coronary angio-
gram) of distal left ITA grafted for moderately stenosed coronary
arteries. We have to follow up with those patients to look at the fate
of the Y-composite graft.
Dr Zhandong Zhou (Syracuse, NY). I have got a quick ques-
tion. I am just wondering if you see any difference between
a vein graft connected to the left ITA versus a vein graft that con-
nects to the aorta? And second, this was definitely not a blind
study, so do people take a better vein graft for the part that connects
to the mammary artery instead of compared with the vein graft
connected to the aorta?
Dr Hwang. The theoretical advantages of using the saphenous
vein as a composite graft based on the internal thoracic artery
are, first, the saphenous vein is not exposed to direct pressure and
circulatory stress from the ascending aorta and, second, the saphe-
nous vein is exposed continuously to nitric oxide produced from the
in situ left ITA, which may reduce the risk of atherosclerotic
disease.
Dr Zhou.My question is do you see any difference in terms of
patency rate compared with a vein graft connected to the left ITA
versus a vein graft to the aorta? Is there any difference in 1 year?
Dr Hwang. You mean patency rate?
Dr Zhou. Yes.
Dr Hwang. In our previous study, the 1-year patency rate of sa-
phenous vein used in an aortocoronary fashion was<80%. In con-
trast, we recently published in the Annals of Thoracic Surgery thatgery c November 2012
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1 year.
Dr Zhou. Is that the same group of patients or a different group
of patients? So they are not comparable, right?
DrHwang.No, they are not comparable. It is a limitation of ret-
rospective studies.
Dr Zhou. It is in the same group?
Dr Hwang.No, they are not the same groups. We have changed
our strategy in 2006; most aortocoronary saphenous bypasses were
performed before 2006, and most saphenous vein composite grafts
were constructed since 2006.The Journal of Thoracic and CarDr Zhou. But do you see any difference between the second
graft and the third graft in your same group, because the third graft
was a vein graft, right?
Dr Hwang. I am afraid that you misunderstand our third
vein graft being anastomosed to the aorta. The third graft
was connected to the left ITA or to the second graft as an I
shape instead of to the aorta. In our previous retrospective
study, we compared the patency rate of the second arterial
composite and third vein composite grafts. There were no
differences in patency rates between the second and third com-
posite grafts.diovascular Surgery c Volume 144, Number 5 1035
